United States Patent 6,419,958: Scope, Claim Architecture, and US Landscape for Venlafaxine ER Dosing
United States Patent US 6,419,958 is directed to oral venlafaxine hydrochloride extended-release (ER) regimens that target a specific venlafaxine plasma Cmax timing window (about 4 to 8 hours, and narrower variants about 5 to 8 hours and about 6 hours) with an asserted reduced incidence of nausea and emesis, and with a secondary dosing effect framed as reducing trough-to-peak fluctuation for venlafaxine plasma concentration profiles.
What is the core invention in US 6,419,958?
Claim theme: “Extended release venlafaxine hydrochloride” administered orally to achieve:
1) 24-hour therapeutic plasma exposure, with
2) diminished nausea and emesis (Claims 1, 3, 4), and
3) reduced troughs and peaks during plasma concentration fluctuation (Claims 2, 5, 6),
all anchored to the same pharmacokinetic control knob:
- Cmax occurs in a defined time interval after dosing, specifically:
- about 4 to about 8 hours (Claims 1 and 2),
- about 5 to about 8 hours (Claims 3 and 5),
- about 6 hours (Claims 4 and 6).
Key structural observation: The patent is written as method claims for providing or achieving plasma concentration profiles, not as composition claims in the text you provided. The controlling limitation across all claims is the ER formulation producing a peak (Cmax) at the specified time.
What do the independent limitations require, claim-by-claim?
Claim 1
A method for providing a therapeutic venlafaxine plasma concentration over 24 hours with diminished incidence of nausea and emesis, comprising:
- Oral administration to a patient in need thereof of an ER formulation
- ER formulation has Cmax at about 4 to about 8 hours
- Active ingredient is venlafaxine hydrochloride
Claim 2
A method for eliminating troughs and peaks of venlafaxine plasma concentration during the therapeutic metabolism of plural daily doses, comprising:
- Oral administration of an ER formulation
- Cmax at about 4 to about 8 hours
- Active ingredient is venlafaxine hydrochloride
Claim 3
Like Claim 1, but with a narrower Cmax timing window:
- Cmax at about 5 to about 8 hours
Claim 4
Like Claim 1, with a single-point timing anchor:
Claim 5
Like Claim 2, but narrowed:
- Cmax at about 5 to about 8 hours
Claim 6
Like Claim 2, single-point:
How broad is the claim scope?
1) “Extended release formulation” scope
The claims, as provided, are agnostic to:
- dosage strength,
- polymer system,
- release mechanism (matrix vs reservoir),
- tablet/capsule format,
- excipient selection,
- number of daily doses (except Claim 2/5/6 mention “plural daily doses”).
The only formulation-level requirement visible in the claim text is: it is an ER formulation that yields the specified Cmax time and contains venlafaxine hydrochloride.
2) “Cmax timing window” is the main boundary
The claim scope is best modeled as a pharmacokinetic time-of-peak constraint:
| Claim set |
Cmax limitation in claim |
Practical claim boundary implication |
| Claims 1 and 2 |
“in from about 4 to about 8 hours” |
Covers ER products that yield Cmax in that broad mid-window |
| Claims 3 and 5 |
“in from about 5 to about 8 hours” |
Narrows to later-peaking profiles within the broader window |
| Claims 4 and 6 |
“in about 6 hours” |
Targets products with Cmax tightly centered around 6 hours |
Interpretive pressure point: The phrase “about” creates tolerance, but the claims still require that the product’s observed Cmax timing fits the stated windows when tested under relevant conditions.
3) Therapeutic objective limitations vs concentration profile control
Two alternative “method purposes” appear:
- Reduced nausea/emesis objective (Claims 1, 3, 4)
- Reduced troughs/peaks objective (Claims 2, 5, 6)
These are not backed in the claim text by specific quantitative thresholds (e.g., incidence percentages or measurable trough/peak metrics). In enforcement terms, the claims tether compliance to achievement of the plasma profile and ER behavior (via the Cmax constraint), while the adverse-event and fluctuation language frames the intended outcome.
What is the claim structure for infringement risk?
A product designed to avoid infringement would focus on at least one of these claim anchors:
1) Active ingredient: use something other than venlafaxine hydrochloride (the claims require venlafaxine hydrochloride).
2) Oral administration: the claims require oral administration.
3) Extended release classification: not “immediate release.”
4) Cmax timing: shift Cmax outside the claimed “about” ranges.
Cmax timing as the primary “design-around” axis
The strongest “engineering” constraint is the Cmax timing. A competitor seeking to enter with a venlafaxine ER product would attempt to position Cmax outside:
- 4 to 8 hours (for Claims 1 and 2 coverage),
- 5 to 8 hours (for Claims 3 and 5 coverage),
- around 6 hours (for Claims 4 and 6 coverage).
If a product’s Cmax is measured in the claimed windows, it is exposed to at least the claims whose Cmax limitation matches.
Is the patent’s scope limited to once-daily dosing?
The claim text you provided does not state “once daily” as a global requirement. It specifies “plural daily doses” in the troughs/peaks-elimination claims (Claims 2, 5, 6). That means:
- Claims 1, 3, 4 can be read on a 24-hour plasma maintenance method that could be consistent with once-daily or other dosing schedules, as long as the method provides 24-hour therapeutic concentration and the nausea/emesis reduction objective is met.
- Claims 2, 5, 6 explicitly contemplate plural daily dosing, which may align with clinical regimens involving more than one daily administration.
For landscape analysis, this matters because it broadens potential coverage beyond strict once-daily ER use.
Patent landscape: where this sits relative to venlafaxine ER and formulation/IP trends in the US
1) The patent is about method-of-use/PK-timing rather than composition novelty
Many formulation patents in CNS and antidepressants target polymer systems, coatings, and ER release mechanisms; method-of-use claims based on PK targets are a common IP strategy to protect efficacy-like outcomes without requiring a unique composition.
US 6,419,958’s claim text you provided is consistent with this pattern:
- it is method-based,
- it is anchored to pharmacokinetic performance (Cmax timing),
- it uses clinical tolerability framing (nausea/emesis) as part of the therapeutic method.
2) Practical enforcement hook: clinical PK studies
Because the claim language is keyed to Cmax timing, enforcement and validity arguments typically depend on:
- study design,
- sampling schedule adequate to identify the true peak time,
- statistical reporting of “about” time windows.
That makes US 6,419,958 especially relevant to disputes over whether an accused ER formulation produces a peak venlafaxine plasma concentration in the claimed time range.
3) Likely overlap with other venlafaxine ER exclusivities
The broader venlafaxine ER US landscape generally includes:
- formulation patents (controlled release matrices, beads, coatings),
- patent families protecting specific ER technologies,
- later improvements (dosing regimens and tolerability-related method claims),
- method-of-use or label-driven exclusivities around ER dosing versus IR.
Within that ecosystem, US 6,419,958’s value proposition is its PK-timing-based method claims. That often overlaps with other ER patents that also aim to control Cmax (and thereby reduce side effects associated with higher peaks).
4) Expiration and enforcement horizon
The patent number indicates a filing/issuance era typical for early 2000s formulation/IP. For business planning, the effective enforcement horizon is tied to:
- expiration of the patent term,
- any patent term adjustments,
- any terminal disclaimers,
- and whether continuation/divisional family members exist (not provided in your input).
Because those family details were not supplied, the only provable conclusion from your input is scope-based, not term-based.
Scope chart: which claim is implicated by which PK profile
| Observed product behavior (venlafaxine ER Cmax timing) |
Claims potentially implicated |
| Cmax occurs “about 6 hours” |
Claims 4 and 6 (also possibly Claims 1/2/3/5 if “about 4-8” and/or “about 5-8” are satisfied) |
| Cmax occurs “about 5 to about 8 hours” but not around 6 |
Claims 3 and 5 |
| Cmax occurs “about 4 to about 8 hours” but outside “about 5 to about 8 hours” |
Claims 1 and 2 (depending on whether Cmax is within 4 to 5 hours band) |
| Cmax occurs outside “about 4 to about 8 hours” |
Claims 1-6 likely not met on the Cmax limitation |
This highlights why the measured Cmax time is central to both freedom-to-operate decisions and product positioning.
Business implications for R&D and FTO
1) Formulation development targets a legal boundary
R&D teams optimizing ER venlafaxine for reduced side effects often tune:
- absorption rate,
- release kinetics,
- food effect profile,
- site and extent of absorption.
US 6,419,958 turns that PK optimization into a litigation-relevant boundary. The legal target is not simply “flatter exposure,” but timing of the peak.
2) PK study design can decide claim coverage
If challenged, the measurement of “peak plasma level … in about X hours” can become dispositive. Teams should ensure that clinical/BE studies have:
- sufficient sampling density in the early-to-mid absorption window,
- consistent reporting of Cmax time,
- alignment with the conditions that the regulatory study would represent.
3) Tolerability outcome is claim-framing, not a numeric threshold
Claims 1, 3, and 4 add “diminished incidence of nausea and emesis,” but the claim text you provided does not specify thresholds. That means the PK Cmax limitation still drives the technical match, while nausea/emesis language can become evidence-based support rather than a strict numeric gating element, depending on how courts treat method claim outcome limitations.
Key Takeaways
- US 6,419,958 is a venlafaxine hydrochloride ER oral method patent, with the central enforceable limitation being Cmax time: about 4 to 8 hours, about 5 to 8 hours, or about 6 hours.
- Claims 1/3/4 add a tolerability objective: diminished nausea and emesis while maintaining therapeutic 24-hour plasma concentration.
- Claims 2/5/6 add a plasma fluctuation objective: eliminating troughs and peaks under plural daily dosing.
- The patent’s practical “design-around” lever is shifting the ER product’s Cmax time outside the claimed windows.
- Because the claims are method-of-use and PK-timing anchored, they are most sensitive to bioavailability and PK study outcomes, especially Cmax time determination.
FAQs
1) What part of the claims is most likely to be litigated technically?
The Cmax timing requirement (about 4 to 8, 5 to 8, or about 6 hours) because it is a measurable pharmacokinetic endpoint used to map an accused ER product to the claim limitations.
2) Does the patent require a specific dosage strength?
No dosage strength is specified in the claim language you provided. The key constraints are ER oral venlafaxine hydrochloride and Cmax timing.
3) Are nausea and emesis reductions numerically defined in the claim text you provided?
No numeric thresholds are included in the provided claim language. The claims recite “diminished incidence,” tied to the method’s therapeutic profile.
4) Does the patent mention once-daily dosing explicitly?
Not in the claim language you provided. It specifies “plural daily doses” only for the trough/peak elimination claims.
5) What is the cleanest way to avoid coverage, based on the claim text?
Deliver an oral ER venlafaxine product where Cmax time falls outside the claimed windows and ensure the method does not otherwise satisfy the explicit limitations (including venlafaxine hydrochloride).
References
[1] United States Patent 6,419,958 (venlafaxine extended-release plasma concentration methods; claims as provided by user).
